Search Results for "covid"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for covid. Results 11 to 20 of 93 total matches.
Timing of Remdesivir for COVID-19
The Medical Letter on Drugs and Therapeutics • Oct 19, 2020 (Issue 1609)
Timing of Remdesivir for COVID-19 ...
Remdesivir (Veklury – Gilead), an investigational
antiviral drug administered by IV infusion, is now
available through an FDA Emergency Use Authorization
(EUA) for treatment of COVID-19 in all hospitalized
patients. An earlier EUA limited use of the drug to
patients hospitalized with severe disease.
Remdesivir (Veklury) for COVID-19
The Medical Letter on Drugs and Therapeutics • Nov 30, 2020 (Issue 1612)
Remdesivir (Veklury) for COVID-19 ...
The FDA has approved the antiviral drug remdesivir
(Veklury – Gilead) for IV treatment of COVID-19 in
hospitalized patients who are ≥12 years old and weigh
≥40 kg. Hospitalized children who are <12 years old
or weigh <40 kg can receive remdesivir through an
Emergency Use Authorization (EUA). Remdesivir is
the first drug to be approved in the US for treatment
of COVID-19.
Paxlovid for Treatment of COVID-19
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022 (Issue 1642)
Paxlovid for Treatment of COVID-19 ...
On December 22, 2021, the FDA issued an Emergency
Use Authorization (EUA) for the investigational
antiviral drug nirmatrelvir copackaged with the HIV-1
protease inhibitor ritonavir (Paxlovid – Pfizer) for
oral treatment of mild to moderate COVID-19 in
outpatients ≥12 years old who weigh at least 40 kg
and are at high risk of progressing to severe disease,
including hospitalization or death. Paxlovid was the
first oral antiviral drug to be authorized in the US for
treatment of COVID-19; Merck's oral antiviral drug
molnupiravir was granted an EUA for treatment of
COVID-19 on...
Some Drugs for COVID-19
The Medical Letter on Drugs and Therapeutics • Apr 06, 2020 (Issue 1919)
Some Drugs for COVID-19 ...
The severity and rapid spread of COVID-19 (caused by SARS-CoV-2) have raised questions about the use of some drugs in patients with the disease and whether currently available drugs could be effective in treating it. Definitive answers are lacking, but some recommendations can be made. For additional information on specific drugs, see our table Some Drugs Being Considered for Treatment of COVID-19.
Med Lett Drugs Ther. 2020 Apr 6;62(1919):1 doi:10.58347/tml.2020.1919a | Show Introduction Hide Introduction
COVID-19 Update: Bivalent Pfizer and Moderna COVID-19 Vaccines for Booster Immunization
The Medical Letter on Drugs and Therapeutics • Oct 03, 2022 (Issue 1660)
COVID-19 Update: Bivalent Pfizer and Moderna COVID-19 Vaccines for Booster Immunization ...
The FDA has amended its Emergency Use Authorizations
(EUAs) for the mRNA COVID-19 vaccines
manufactured by Pfizer/BioNTech (Comirnaty)
and Moderna (Spikevax) to permit use of bivalent
formulations of the products as a single booster dose
in persons ≥12 years old (Pfizer) or ≥18 years old
(Moderna) whose most recent COVID-19 vaccine dose
was a monovalent product given ≥2 months previously
as a booster or for completion of a primary series. The
bivalent formulations are not authorized for primary
immunization. Monovalent Pfizer and Moderna
COVID-19 vaccines are no longer...
An EUA for Tocilizumab (Actemra) for COVID-19
The Medical Letter on Drugs and Therapeutics • Jul 26, 2021 (Issue 1629)
An EUA for Tocilizumab (Actemra) for COVID-19 ...
The interleukin-6 (IL-6) receptor antagonist tocilizumab (Actemra – Genentech) has received an
Emergency Use Authorization (EUA) from the FDA for IV treatment of COVID-19 in hospitalized patients ≥2
years old who are receiving a systemic corticosteroid and require supplemental oxygen, mechanical
ventilation, or extracorporeal membrane oxygenation (ECMO). Tocilizumab has been approved by the FDA
for various indications, including rheumatoid arthritis and juvenile idiopathic arthritis.
An EUA for Sotrovimab for Treatment of COVID-19
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021 (Issue 1627)
An EUA for Sotrovimab for Treatment of COVID-19 ...
The investigational monoclonal antibody sotrovimab
(VIR-7831; GSK/Vir Biotechnology) has been granted
an FDA Emergency Use Authorization (EUA) for
treatment of mild to moderate COVID-19 in patients
≥12 years old who weigh ≥40 kg and are at high
risk of progressing to severe disease, including
hospitalization and death.1 Two other monoclonal
antibody regimens are authorized for the same
indication: casirivimab (REGN10933) and imdevimab
(REGN10987) administered together, and bamlanivimab (LY-CoV555) and etesevimab (LYCoV016)
administered together.
The FDA revoked its EUA...
An EUA for Casirivimab and Imdevimab for COVID-19
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020 (Issue 1614)
An EUA for Casirivimab and Imdevimab for COVID-19 ...
The FDA has issued an Emergency Use Authorization
(EUA) for Regeneron's investigational monoclonal
antibodies casirivimab and imdevimab (REGEN-COV)
to be administered together by IV infusion or SC
injection for treatment of mild to moderate COVID-19
in adults and pediatric patients (≥12 years old and
weigh ≥40 kg) who are at high risk of progressing to
severe COVID-19 and/or hospitalization.
An EUA for Bebtelovimab for Treatment of COVID-19
The Medical Letter on Drugs and Therapeutics • Mar 21, 2022 (Issue 1646)
An EUA for Bebtelovimab for Treatment of COVID-19 ...
The investigational monoclonal antibody
bebtelovimab (LY-CoV1404 – Lilly) has been granted
an FDA Emergency Use Authorization (EUA) for IV
treatment of mild to moderate COVID-19 in patients
≥12 years old who weigh ≥40 kg and are at high
risk of progressing to severe disease, including
hospitalization and death, and for whom alternative
treatment options are unavailable or inappropriate.
Bebtelovimab is active against the Omicron variant of
SARS-CoV-2; sotrovimab (VIR-7831) is the only other
monoclonal antibody currently available for treatment
of COVID-19 that is active...
Booster Doses of COVID-19 Vaccines
The Medical Letter on Drugs and Therapeutics • Nov 29, 2021 (Issue 1638)
Booster Doses of COVID-19 Vaccines ...
The FDA has expanded the Emergency Use Authorizations
(EUAs) for the mRNA-based COVID-19 vaccines
manufactured by Pfizer/BioNTech (Comirnaty) and
Moderna (Spikevax) and the adenovirus-based vaccine
manufactured by Johnson & Johnson/Janssen to
include administration of a booster dose in select
populations after primary immunization with either the
same COVID-19 vaccine or a different one.